Our findings add to the preclinical evidence supporting the potential use of G-CSF to reduce HT associated with delayed tPA therapy [12] and also address a STAIR guideline regarding efficacy assessments of drug candidates in multiple ischemia models prior to clinical development [13]. The gene discussed is CSF3; the disease is ischemia.